Skip to main content
. 2020 Sep 10;73(7):e1624–e1631. doi: 10.1093/cid/ciaa1365

Figure 6.

Figure 6.

Pretreatment with reslizumab did not reduce the number or severity of post-treatment adverse events (AE). The number of AEs reported in each group during the first 10 days post-treatment is shown in A. B shows the severity of these post-treatment reactions in individual subjects who received reslizumab (subjects 1–4) or placebo (subjects 5–8). Abbreviation: DEC, diethylcarbamazine citrate.